Dr. Reddy's Laboratories Clarifies Semaglutide Injection Status with Health Canada
Dr. Reddy's Laboratories Ltd. issued a clarification on April 24, 2026, regarding a news item published on CNBC TV18 on April 23, 2026. The news item, titled "Dr. Reddy's Laboratories still awaiting approval for a major near-term trigger, sources say," focused on the regulatory status of the company's Semaglutide Injection.The company confirmed that the headline reported by CNBC TV18 is accurate, stating that Dr. Reddy's Laboratories has not yet received the 'Notice of Compliance' for its Semaglutide Injection from Health Canada.
Despite the pending approval, Dr. Reddy's Laboratories reported a key development in the regulatory process. The company successfully received the 'Drug Identification Numbers (DINs)' for Semaglutide Injection from Health Canada on April 22, 2026.
The company emphasized its continued efforts to move the product through the regulatory channels and remain focused on bringing the Semaglutide Injection to the Canadian market upon receiving the necessary final approvals.
DRREDDY Stock Price Movement
As of 9:31 AM, shares of Dr. Reddy's Laboratories Limited are slipping by 2.28% in live trading, currently trading at ₹1300.6. The stock has seen significant activity, trading on a volume of 604,386 shares as the market continues to make moves.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.